These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 25138242)
1. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Mou X; Zhou Y; Jiang P; Zhou T; Jiang Q; Xu C; Liu H; Zheng T; Yuan G; Zhang Y; Chen D; Mao C Sci Rep; 2014 Aug; 4():6138. PubMed ID: 25138242 [TBL] [Abstract][Full Text] [Related]
2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
3. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428 [TBL] [Abstract][Full Text] [Related]
4. Natural killer cell-mediated shedding of ULBP2. Wang R; Sun PD PLoS One; 2014; 9(3):e91133. PubMed ID: 24614922 [TBL] [Abstract][Full Text] [Related]
5. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications. Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211 [TBL] [Abstract][Full Text] [Related]
6. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260 [TBL] [Abstract][Full Text] [Related]
7. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia. Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181 [TBL] [Abstract][Full Text] [Related]
8. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393 [TBL] [Abstract][Full Text] [Related]
9. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547 [TBL] [Abstract][Full Text] [Related]
10. NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. Osterburg AR; Nelson RL; Yaniv BZ; Foot R; Donica WR; Nashu MA; Liu H; Wikenheiser-Brokamp KA; Moss J; Gupta N; McCormack FX; Borchers MT JCI Insight; 2016 Oct; 1(16):e87270. PubMed ID: 27734028 [TBL] [Abstract][Full Text] [Related]
11. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. Park MJ; Bae JH; Chung JS; Kim SH; Kang CD Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289 [TBL] [Abstract][Full Text] [Related]
12. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492 [TBL] [Abstract][Full Text] [Related]
13. ULBP3: a marker for alopecia areata incognita. Moftah NH; El-Barbary RA; Rashed L; Said M Arch Dermatol Res; 2016 Aug; 308(6):415-21. PubMed ID: 27142445 [TBL] [Abstract][Full Text] [Related]
14. [Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. Huang YX; Wang Y; Sun M; Zhou XY; Deng L; Guo KY Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1329-32. PubMed ID: 19620045 [TBL] [Abstract][Full Text] [Related]
15. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Song H; Kim J; Cosman D; Choi I Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603 [TBL] [Abstract][Full Text] [Related]
16. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960 [TBL] [Abstract][Full Text] [Related]
17. NKG2D Signaling between Human NK Cells Enhances TACE-Mediated TNF-α Release. Sharma N; Trinidad CV; Trembath AP; Markiewicz MA J Immunol; 2017 Oct; 199(8):2865-2872. PubMed ID: 28893955 [TBL] [Abstract][Full Text] [Related]
18. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells]. Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338 [TBL] [Abstract][Full Text] [Related]
19. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476 [TBL] [Abstract][Full Text] [Related]
20. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]